baber/WOPTO huggingface dataset:
Patent NZ-528332-A (NZ)
Title: Impact driver for driving poles, piles or posts including linear induction motor
Inventor: KENNETT DAVID
Filed: 2003-09-22
Abstract: Typically the impact driver 102 has five primary components: chassis 3; ram/reactor support 18, anvil 32, stator component of a linear induction motor 16 and support frame 41. Support 18 includes cooperative reactor plate 15. Post 51 can be driven into the ground 102.
Patent NZ-528363-A (NZ)
Title: Liquid suspensions of posaconazole ( SCH 56592 ) with enhanced bioavailability for treating fungal infections
Inventor: SHARPE STEFAN
IPC: A01N43/653
Filed: 2002-04-01
Abstract: A liquid suspension comprises an antifungally effective amount of the micronized compound represented by the structure of formula I, at least one thickening agent, at least one non-ionic surfactant and a pharmaceutically acceptable liquid carrier. The suspension may further comprises an amount of a buffer system suspension to maintain the pH of the system in the range of about 4.0 to about 6.0. Preferably the micronized compound has a mean particle size in the range of about 1200nm to about 1600nm. The suspension can be used in the preparation of a medicament in the form of an oral suspension for the treatment and/or prevention of a fungal infection
Patent NZ-532266-A (NZ)
Title: Juice deacidification
Inventor: LINEBACK D SCOTT
IPC: A23L2/02
Filed: 2002-09-20
Abstract: A system and process for making a low-acid, single strength juice such as a not from concentrate (NFC) citrus juice are provided in which an initial single strength juice flow can be cooled to a temperature of not greater than about 45 DEG F and maintained at that temperature or below throughout the process (except during pasteurization). From the initial juice flow, a first portion of the juice is diverted from a second portion of the juice. Suspended solids are separated out from the first portion to provide a solids-reduced juice. The solids-reduced juice is subjected to ion-exchange deacidification. Preferably, a portion of the initial single strength juice flow is added to the deacidified juice immediately after deacidification in order to immediately lower the pH of the deacidified juice to a value that discourages microbial activity.
Patent NZ-532342-A (NZ)
Title: Fungicidal composition comprising pyrimethanil and at least one phosphorous acid derivative and use of this composition for controlling plant diseases
Inventor: DUVERT PATRICE
IPC: A01N25/30
Filed: 2002-11-08
Abstract: Fungicide compositions comprising pyrimethanil and at least a phosphorus derivative and more particularly a phosphorous acid derivative, and use of such compositions combining the active compounds for fighting against plant diseases or against phytopathogenic fungi present or liable to occur on the plants, wherein such a combination particularly enables to prolong in time the pyrimethanil activity are disclosed.
Patent NZ-535337-A (NZ)
Title: Method of purifying a pesticide
Inventor: FINCH CHARLES WILLIAM
IPC: A01N47/20
Filed: 2003-03-25
Abstract: Disclosed is a method of purifying a pesticide comprising: a) melting a pesticide, wherein the pesticide comprises at least one active ingredient and at least one impurity capable of inhibiting crystallization; b) coating the pesticide on a substrate to form a pesticide particle; c) substantially reducing the amount of crystallization inhibiting impurity by a azeotropic method; and d) crystallizing the pesticide. Further disclosed is the method wherein the active ingredient is a compound of formula (I).
Patent NZ-537617-A (NZ)
Title: Nucleic acid based assays for accurately diagnosing hepatitis A infection and detecting hepatitis A in a biological sample
Inventor: SHYAMALA VENKATAKRISHNA
IPC: C12Q1/70
Filed: 2003-06-12
Abstract: A set of two primers for amplifying Hepatitis A virus (HAV) nucleic acid derived from the 5'UTR of the HAV genome. The primers can be used to detect the HAV virus in a biological sample. Also disclosed are probe oligonucleotides which comprise a detectable label and a kit for detecting HAV infection.
Patent NZ-541146-A (NZ)
Title: N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide, also known as ACP-103, and its tartrate salt as therapeutics for neurodegenerative diseases
Inventor: WEINER DAVID M
IPC: A61P25/28
Filed: 2004-01-15
Abstract: Disclosed is a compound of Formula (I) or a tartrate salt thereof and a pharmaceutically acceptable carrier. Also disclosed is the use of the above compound or a tartrate salt thereof in the preparation of a medicament for treating a disease condition associated with a monoamine receptor.
Patent NZ-541783-A (NZ)
Title: Event reminder system with setup on a remote server via a website and reminders notified via emails from the server via the internet
Inventor: PIPER JAMES WILLIAM
IPC: G06Q10/00
Filed: 2005-08-12
Abstract: A method of providing at least one reminder of an event is disclosed. The method comprises; (a) issuing, to an email address of a person to be reminded, an email containing information on the event before the time of the event, together with a unique return hypertext URL, (b) receiving a response sent to the unique return hypertext URL, and (c) on receipt of the response, discontinuing issuing reminders of that event to that person, otherwise persistently issuing the reminder with a unique return hypertext URL until the time of the event.
Patent NZ-543446-A (NZ)
Title: High titer recombinant influenza viruses for vaccines and gene therapy
Inventor: KAWAOKA YOSHIHIRO
IPC: C12N15/86
Filed: 2004-05-27
Abstract: Provided is a composition useful to prepare high titer influenza virus in the absence of a helper virus and comprising a sequence from high titer influenza virus isolates. The composition can contain several vectors and hemagglutinin (HA) gene sequences. Further provided are methods to produce said compositions and corresponding gene delivery vehicles.
Patent NZ-543522-A (NZ)
Title: Connective tissue growth factor antibodies
Inventor: LIN AI Y
IPC: C07K16/22
Filed: 2004-06-02
Abstract: Disclosed is an antibody that specifically binds to CTGF and is capable of neutralising a biological activity of CTGF. The antibodies are particularly directed at biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localised and systemic fibrotic disorders of the lung, liver, heart, skin and kidney.
Patent NZ-545692-A (NZ)
Title: PPAR-activating compound and pharmaceutical composition containing same
Inventor: YAMAZAKI YUKIYOSHI
IPC: C07D417/02
Filed: 2004-09-02
Abstract: Disclosed is a compound represented by the following formula (1): wherein Y represents an oxygen atom; Z represents CH or N; X represents an oxygen atom, a sulfur atom, or N-R5; and wherein the rest of the substituents are defined within the specification. Also disclosed is the use of the above compound or a salt thereof in the manufacture of a medicament for treating pathological conditions selected from the group consisting of hyperlipidemia, arteriosclerosis, diabetes, complications of diabetes, inflammation, and heart diseases.
Patent NZ-546204-A (NZ)
Title: Vascular access preservation in haemodialysis patients
Inventor: VOURNAKIS JOHN M
IPC: A61K38/095
Filed: 2004-09-13
Abstract: Disclosed is the use of a composition comprising a barrier-forming material comprising a vasoconstrictor and/or a coagulant, other than bovine thrombin, that promotes wound closure and cessation of bleeding, for the preparation of a medicament for reducing vascular access complications associated with hemodialysis therapy in a patient at risk for said complications, wherein the administration pattern of the medicament comprises: (a) applying said composition topically to the skin at a hemodialysis vascular access site in said patient during a hemodiaIysis session; and (b) applying compression to or proximal to the hemodialysis vascular access site for a duration of about one to about fourteen minutes.
Patent NZ-547429-A (NZ)
Title: Extraction of highly unsaturated lipids with liquid dimethyl ether
Inventor: CATCHPOLE OWEN JOHN
IPC: C11B1/00
Filed: 2006-05-24
Abstract: Disclosed is a process for obtaining highly unsaturated fatty acids from a marine animal, plant or micro-organism material, comprising the steps: (i) contacting the material with liquid dimethyl ether, (ii) separating the resultant solution and residue, and (iii) recovering the lipids under pressure from the solution.
Patent NZ-552812-A (NZ)
Title: N-phenylphosphoric acid triamides, method for the production thereof and their use as agents for regulating or inhibiting enzymatic urea hydrolysis
Inventor: HUCKE ANDRE
IPC: C05G3/90
Filed: 2005-02-04
Abstract: Disclosed are phosphoric acid triamides of formula (I), where X is oxygen or sulfur, and wherein the rest of the subtituents are disclosed in the specification, and a method of making these compounds. Also disclosed is a fertiliser composition containing the compound for urease inhibition or nitrification inhibition, in order to reduce the ammonia presence of dung or excrement and to avoid toxic effects for animals. Also disclosed is the use of the compositions for fertigation, or for producing a drug to treat dysfunction and diseases associated with urease actvity, such as catheter encrustation, inflamed and ulcerous stomach and bowel diseases, urolithiasis, pyelonephritis, nephrolithiasis, ammonia encephalopathy, hepatic encephalopathy, hepatic coma, infections of the urinary passage and gastrointestinal infections, including those caused by helicobacter pylori.
Patent NZ-562771-A (NZ)
Title: Anti-IL-6 antibodies, compositions, methods and uses
Inventor: CHEN YAN
IPC: A61K39/395
Filed: 2006-04-28
Abstract: Provided is an isolated IL-6 antibody corresponding to a specified DNA and amino acid sequence of the light and heavy chain variable regions. The antibody can be combined with other drugs. Further provided are anti-idiotype antibodies that specifically bind to the antibody.
Patent NZ-564366-A (NZ)
Title: Sodar sounding of the lower atmosphere where backscattered echoes are detected by receivers located near the transmitter
Inventor: MARTIN ANDREW LOUIS
IPC: G01S13/95
Filed: 2006-06-15
Abstract: Disclosed is a monostatic sodar system (10) for generating information about atmospheric parameters over an altitude range. The system includes at least three peripheral transmitter-receiver pairs arranged substantially equidistant on a circle (11), with the transmitter (T) and receiver (R) of each of the pairs tilted radially outward with respect to the circle at an angle to the vertical. Each transmitter and receiver comprises an acoustic transducer (12), an acoustic reflector (14) and a surrounding baffle (16), such that acoustic echoes returned from the atmosphere resulting from acoustic transmissions of one transmitter are preferentially received by the receiver of the respective pair relative to all other receivers. The system further includes signal processing means connected to each pair and adapted to: cause at least one transmitter of a transmitter-receiver pair to transmit an encoded acoustic signal into the atmosphere; and process signals received by the receiver of the respective pair during the transmission of the acoustic signal and for a time interval thereafter so as to derive information indicative of the atmospheric parameters with respect to altitude. The signal processing means includes a matched filter to process the received signal by reference to the encoding of the acoustic signal.
Patent NZ-564480-A (NZ)
Title: Use of selective cytokine inhibitory drugs for the treatment of Behcet's disease
Inventor: ZELDIS JEROME B
IPC: A61K31/425
Filed: 2003-11-06
Abstract: Use of a selective cytokine inhibitory drug selected from cyclopropyl-N-{2[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide, which has the structure (I) as shown herein, and pharmaceutically acceptable salts and solvates thereof, in the preparation of a composition for treating Behcet's disease is disclosed.
Patent NZ-566036-A (NZ)
Title: 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
Inventor: THURING JOHANNES WILHELMUS JOHN F
IPC: C07D277/42
Filed: 2006-09-05
Abstract: Disclosed is the use of compounds of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the substituents are as defined in the specification, for treating psychotic disorders, intellectual impairment disorders, or disorders in which modulation of the á7 nicotinic receptor is beneficial. Also disclosed are specific compounds which fall within formula (I), or pharmaceutically acceptable salts or stereoisomers thereof.
Patent NZ-566944-A (NZ)
Title: N-(2-aminophenyl)-4-{1-[(pyrazol-4-yl)methyl]piperidin-4-yl}benzamide derivatives for the treatment of cancer
Inventor: ANDREWS DAVID MICHAEL
IPC: A61K31/4155
Filed: 2006-10-17
Abstract: Disclosed are N-(2-aminophenyl)-4-{1-[(pyrazol-4-yl)methyl]piperidin-4-yl}benzamide derivatives as represented by the general formula (IA), wherein R2, R3 and R5 are each independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof. Of particular importance are the compounds N-(2-aminophenyl)-4-{1-[(1-methyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, N-(2-aminophenyl)-4-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, N-(2-aminophenyl)-4-{1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide and N-(2-aminophenyl)-4-{1-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide. Also disclosed is a pharmaceutical composition which comprises a compound as defined above in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancers such as lung cancer, colorectal cancer, breast cancer, prostate cancer, lymphoma or leukaemia.
Patent NZ-568653-A (NZ)
Title: A concentrate derived from a milk product enriched in naturally occurring sialyl-lactose and a process for preparation thereof
Inventor: HOLST HANS HENRIK
IPC: A61K31/00
Filed: 2006-11-03
Abstract: Disclosed is a process for the preparation of a concentrate derived from a milk product enriched in the naturally occurring sialyllactose in the milk product comprising ultrafiltration of a milk product containing sialyllactose followed by diafiltration and optionally reverse osmosis and or/drying. The membrane has a molecular weight cut off (MWCO) value which is about 0.5 - 4 k Dalton. Also claimed is a concentrate obtained from the process.
Patent NZ-577439-A (NZ)
Title: Novel method for the diastereoselective production of a chiral primary amine on a steroid
Inventor: BERNARD DANIEL
IPC: C07J41/00
Filed: 2007-12-11
Abstract: Disclosed herein is a process for the stereoselective preparation of steroid primary amines of alpha- or beta- configuration, at positions 1, 2, 3, 4, 6, 7, 11, 12, 15, 16 or 17 on the steroid backbone wherein an oxime of formula (II) is treated with lithium metal in liquid ammonia, at a temperature of between -33°C and -90°C, in a mixture of a solvent of ether type and of an aliphatic alcohol, and the compound of formula (I) is obtained, in which the amine of alpha- or beta- configuration is in the position corresponding to that of the oxime on the compound of formula (II), wherein the substituents are as defined within the specification.
Patent NZ-578310-A (NZ)
Title: Mapk/erk kinase inhibitors
Inventor: DONG QING
IPC: C07D471/04
Filed: 2007-12-18
Abstract: Disclosed is a compound having the formula (I) e.g. 5-(2-fluoro-4-iodophenylamino)-3,8-dimethylpyrido [2,3-d]pyrimidine-4,7(3H,8H)-dione or a solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein X1, X5, R1, R2, R3 and R5 are as defined in the specification for treating cancerous hyperproliferative disorders; non-cancerous hyperproliferative disorders; pancreatitis; kidney disease; pain; preventing blastocyte implantation; treating diseases related to vasculogenesis or angiogenesis; asthma; neutrophil chemotaxis; septic shock; T-cell mediated diseases where immune suppression would be of value; atherosclerosis; inhibition of keratinocyte responses to growth factor cocktails; and chronic obstructive pulmonary disease (COPD).
Patent NZ-579815-A (NZ)
Title: Electrolysis cells where the cathode bars have a combination of vertical and horizontal outlets
Inventor: OVSTETUN FRANK
IPC: C25C3/16
Filed: 2008-03-10
Abstract: A method for operating electrolysis cells connected in series, where electrical current is led into one first cell via an anode arrangement arranged in the upper part of the cell, through an electrical conducting electrolyte and further through a substantially horizontal cathode, and further to an anode arrangement of a neighbouring cell, via one or more risers 6 and where electric current is led vertically out of the cell from at least one intermediate position of the cathode by means of at least one connection and further downstream the cathode is connected to the one or more risers 6 where current is conducted from the cathode via at least one collector bar 12 integrated therein. The current is led out of the cathode via the at least one intermediate position in combination with at least one horizontal end of a collector bar 12.
Patent NZ-580046-A (NZ)
Title: Wave power plant with float(s) set assymetrical to wave advancement and set into gyratory motion
Inventor: PAAKKINEN HEIKKI
IPC: F03B13/14
Filed: 2008-03-28
Abstract: A wave power plant has at least one float or pontoon (1) or a plurality of interconnected floats or pontoons (not shown). The float or pontoon (1) is shaped or the interconnected floats or pontoons are disposed asymmetrically relative to the advancing direction of waves, such that the float or pontoon (1) or a member (not shown) linking the interconnected floats or pontoons is set in a gyrating motion in response to the buoyancy of a succession of waves advancing in said direction. The wave power plant includes elements (5, 6, 7) for converting the gyrating motion into a rotational motion for power take-off.
Patent NZ-581870-A (NZ)
Title: Apparatus for removing pelt from a carcass comprising pair of cylindrical clamping mechanisms that rotate
Inventor: STUCKI PHILIP MARK
IPC: A22B5/00
Filed: 2009-12-09
Abstract: An apparatus (1) for removing pelt from animal carcass is disclosed. The apparatus (1) includes a driving mechanism (11) and a clamping mechanism (2) comprising pair of clamping members (3 and 4). During operation a carcass is placed between the pair of opposing teeth (7) of the two clamping members (3 and 4). The clamping members (3 and 4) then moves relative to each other in opposite directions and then rotate about an axel (9) thereby removing the pelt from the carcass.
Patent NZ-585221-A (NZ)
Title: Peptide deformylase inhibitors comprising pyrimidinyl and hydrazino moieties and crystalline forms thereof
Inventor: QIN DONGHUI
IPC: C07D239/42
Filed: 2008-11-06
Abstract: Disclosed are compounds of Formula (I), crystalline forms thereof, and methods for their preparation. Specific compounds of formula (I) include: [(2R)-3-{ 2-[6-(1-Azetidinyl)-5-fluoro-2-methyl-4-pyrimidinyl]hydrazino} -2-(cyclopentylmethyl)-3-oxopropyl]hydroxyformamide, 6-[(4S)-4-hydroxy-3,3-dimethyl-1-pyrrolidinyl]-2-methyl-4-pyrimidinyl} hydrazino)-3-oxopropyl]hydroxyformamide, and [(2R)-2-(Cyclopentylmethyl)-3-(2-{ 5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl} hydrazino)-3-oxopropyl]hydroxyformamide. Compounds of formula (I) are useful for treating bacterial infections, particularly where the bacterial infection is caused by Streptococcus, Staphylococcus, Moraxella, Haemophilus, Neisseria, Mycoplasma, Legionella, Chlamydia, Bacteroides, Clostridium, Fusobacterium, Propionibacterium, or Peptostreptococcus. Also disclosed are three different crystalline forms of [(2R)-2-(cyciopentylmethyl)-3-(2-{ 5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)yl]-2-methyl-4-pyrimidinyl} hydrazino)-3-oxopropyl]hydroxyformamide. The crystalline polymorphs are characterised with infra-red spectroscopy, X-ray diffraction, thermogravimetric analysis and differential scanning calorimetry
Patent NZ-587583-A (NZ)
Title: Detecting wheel axles using light section line
Inventor: NAGY OLIVER
IPC: G01B11/00
Filed: 2010-08-25
Abstract: Disclosed is a device (1) for detecting wheel axles of a vehicle on a roadway. The device includes a sensor (5), which operates according to a light-section procedure and emits at least one fan of light (9) from a first location along the roadway to project a line of light (10) onto the roadway and a vehicle possibly located thereon. The sensor records this line of light from a second location along the same side of the roadway and detects a wheel axle as soon as the recorded line of light exhibits, in its course emanating from the side of the roadway, a shift-free change in direction differing from its course when the roadway is empty.
Patent NZ-588432-A (NZ)
Title: Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
Inventor: LINDQUIST SUSAN L
IPC: A61K31/4164
Filed: 2005-09-16
Abstract: Disclosed are compounds represented by general formula (I), wherein X is O, S or NR, and R25 and R26 together form a heterocyclyl or heteroaryl ring. Also disclosed is the use of the compounds of formula (I) for inhibiting or preventing alpha-synuclein toxicity and/or fibril formation, inhibiting or preventing alpha-synuclein fibril growth, and/or causing disassembly, disruption, and/or disaggregation of alpha-synuclein fibrils and alpha-synuclein-associated protein deposits.
Patent NZ-588545-A (NZ)
Title: Optical method for determining morphological parameters and physiological properties of a lesion
Inventor: STAMNES JAKOB J
IPC: A61B5/1455
Filed: 2009-03-18
Abstract: 588545 An optical method for determining morphological parameters and physiological properties of tissue, the method comprising the steps of: generating, using an optical transfer diagnosis device, 30 reflectance images comprising reflectance measurements from a tissue area for 10 different wavelengths from multiple angles of illumination and detection and using the reflectance measurements to determine morphological parameters and physiological parameters. Determining the morphological parameters comprises using one of the 30 reflectance images for: determining a lesion border from the reflected intensity of the image of the lesion from a visible channel, measuring a size of the lesion, measuring a histogram-width that gives a measure of inhomogeneity of the reflected intensity of the lesion, capturing a relative moment of inertia of the lesion, determining a center distance representing a physical distance between a geometrical center of the lesion and a center of mass of absorptance, determining a fractal dimension of the lesion which describes the complexity of its border, determining an asphericity of the lesion, and determining a relative border length of the lesion. Determining the morphological and physiological parameters comprises, by using a bio-optical model, radiative transfer modeling, and a non-linear inversion procedure: systematically varying input values of the morphological parameters and physiological properties of the tissue while simultaneously varying inherent optical properties, the inherent optical properties being linked to the morphological parameters and the physiological properties of the tissue, computing reflectances by the radiative transfer model until an agreement between the reflectance measurements and reflectances computed by the radiative transfer model reaches a predetermined level of accuracy, and obtaining the morphological parameters and the physiological properties returned by the non-linear inversion procedure.